About: Clinical Performance of SARS-CoV-2 Molecular Testing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Performance of SARS-CoV-2 Molecular Testing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical Performance of SARS-CoV-2 Molecular Testing
Creator	Whittier, Susan Sobieszczyk, Magdalena Westblade, Lars Green, Daniel Boehme, Amelia Cushing, Melissa Liu, Dakai Rennert, Hanna Sepulveda, Jorge Zucker, Jason Craney, Arryn Velu, Priya Sepulveda,
source	MedRxiv
abstract	Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the test clinical performance is poorly understood. From 3/10/2020-5/1/2020 NewYork-Presbyterian laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat testing was performed in 3,432 patients, of which 2,413 had negative and 1,019 had positive first day results. Repeat-tested patients were more likely to be older, male, African-American or Hispanic, and to have severe disease. Among the patients with initially negative results, 18.6% became positive upon repeat-testing. Only 58.1% of any-time positive patients had a result of %22detected%22 on the first test. The clinical sensitivity of COVID-19 molecular assays is estimated between 66.2% and 95.6%, depending on the unknown number of false negative results in single-tested patients. Conversion to a negative result is unlikely to occur before 15 to 20 days after initial testing or 20-30 days after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing. Forty-nine initially-positive patients converted to negative and then back to positive in subsequent days. Conversion from first day negative to positive results increased linearly with each day of testing, reaching 25% probability in 20 days. In summary, our study provides estimates of the clinical performance of SARS-CoV-2 molecular assays and suggests time frames for appropriate repeat testing, namely 15 to 20 days after a positive test and the same or next 2 days after a negative test in a patient with high suspicion for COVID-19.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1101/2020.05.06.20093575
has license	medrxiv
sha1sum (hex)	5af46f7015d719006319f3e12bbe9ac49a250603
schema:url	https://doi.org/10.1101/2020.05.06.20093575
resource representing a document's title	Clinical Performance of SARS-CoV-2 Molecular Testing
resource representing a document's body	covid:5af46f7015d719006319f3e12bbe9ac49a250603#body_text
is schema:about of	named entity 'diagnosis' covid:arg/5af46f7015d719006319f3e12bbe9ac49a250603 named entity 'SARS-CoV-2' named entity 'molecular' named entity '5/1' named entity 'Molecular' named entity 'coronavirus disease 2019' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Molecular Testing' named entity 'peer review' named entity 'medRxiv' named entity 'medRxiv' named entity 'probability' named entity 'RT-PCR' named entity 'medRxiv' named entity 'false negatives' named entity 'general population' named entity 'medRxiv' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'emergency department' named entity 'medRxiv' named entity 'peer review' named entity 'medRxiv' named entity 'medRxiv' named entity 'internal control' named entity 'medRxiv' named entity 'Sarbecovirus' named entity 'peer review' named entity 'peer review' named entity 'decompensate' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'stochastic' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'peer review' named entity 'clinical characteristics' named entity 'positive test' named entity 'peer review' named entity 'probability' named entity 'Kaplan-Meier' named entity 'nasopharyngeal' named entity 'medRxiv' named entity 'not-for-profit' named entity 'probability' named entity '7.9' named entity 'medRxiv' named entity 'negative result' named entity 'medRxiv' named entity 'peer review' named entity 'Caucasian race' named entity 'medRxiv' named entity 'medRxiv' named entity 'false negatives' named entity 'medRxiv' named entity 'New York City' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'peer review' named entity 'peer review' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'negative result' named entity 'protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software